Researchers from the Okinawa Institute of Science and Technology have developed a method to study biofilm formation, and how it is affected by drugs, with high efficacy.
ViiV Healthcare has announced positive 48-week results from its Phase III ATLAS study of a long-acting, injectable, two-drug regimen for treating HIV.
The first population-level evidence has proved the rotavirus vaccination saves lives in low-income settings.
New study finds that the oral rotavirus vaccine response could be influenced by changes in the human microbiota.
A study in 20 patients has demonstrated that transplantation followed by antiviral therapy has been successful in patients receiving kidneys from hepatitis C-infected donors.
The first citywide deployment of Wolbachia has proved successful, with no dengue cases reported since Wolbachia became established.
ViiV healthcare has announced results of a 100-week Phase lll program and demonstrated the success of the first two-drug regimen, Juluca®.